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Objective: This open-label study evaluated the effects of combined tocilizumab (TCZ) and
disease-modifying antirheumatic drugs (DMARDs) on magnetic resonance imaging (MRI)
changes in synovial membrane enhancement, bone marrow edema (BME), and erosions in the
wrist and hand joints of rheumatoid arthritis (RA) patients inadequately responding to DMARDs
alone.
Methods: The efficacy of intravenous TCZ 8 mg/kg administered every four weeks for 48 weeks
was evaluated on six occasions. The primary endpoints were the changes in the extent and degree
of wrist synovitis as measured using the RA MRI Score (RAMRIS) and dynamic, gadolinium-
enhanced 0.2TMRI (DCE-MRI). A number of different parameters of DCE-MRI were evaluated.
Results: Fifty-eight patients were treated, eight of whom (13.8%) discontinued the study prema-
turely. The mean RAMRIS significantly decreased after two weeks and the decrease was main-
tained for up to 48 weeks. By week 4, the mean RAMRIS synovitis score had significantly
decreased from baseline (−0.804±1.575; p=0.018), but not the mean early enhancement (REE) or
relative enhancement (RE). However, there were significant decreases in RE at week 24, in REE
andNtotal (total number of enhancing voxels)*IRE (initial rate of enhancement) at weeks 12, 24 and
48, and in Ntotal*ME (maximal enhancement) at weeks 24 and 48. Mean BME decreased from
baseline to week 48, and bone erosions did not progress. The patients’ clinical parameters
significantly improved from baseline until week 48.
Conclusion: TCZ in combination with DMARDs improved wrist synovitis, BME and clinical
parameters, without any progression in bone erosions. The RAMRIS for synovitis rapidly
improved from as early as two weeks after the first TCZ infusion. (Funded by F. Hoffmann–La
Roche; ACTRACE EudraCT No. 2009 012185-32).
Keywords: tocilizumab, rheumatoid arthritis, wrist, synovitis, low-field MRI, dedicated
MRI
There is an increasing need for objective methods to evaluate disease activity and
treatment responses in rheumatoid arthritis (RA). In this setting, magnetic reso-
nance imaging (MRI) has proved to be highly sensitive in detecting inflammatory
and structural changes, and predicting radiological progression.1
Tocilizumab (TCZ) is a recombinant humanised anti-human immunoglobulin
IgG1monoclonal antibody against interleukin-6 receptor (IL-6R), a pleiotropic pro-
inflammatory cytokine produced by synovial and endothelial cells in inflamed areas.2
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A number of randomised clinical trials and several
long-term follow-up studies have demonstrated that it
acts quickly and effectively in RA patients, alone or in
combination with other agents, and suggest that it may
offer an alternative for patients who have shown an inade-
quate clinical response to biological or non-biological,
disease-modifying anti-rheumatic drugs (DMARDs).3–6 It
is still debated if the efficacy of TCZ is in part only
apparent because of its ability to rapidly inhibit the IL-6
mediated C-reactive protein (CRP) production by the
liver.3 A more objective method than clinical and labora-
tory measures could be the evaluation of MRI variables.
The effect of TCZ in RA patients has been previously
studied by means of MRI but the original OMERACT
Rheumatoid Arthritis MRI Score (applied RAMRIS),
which is the preferred method of evaluating MRI in RA,
is not always easy to use in the daily clinical practice.7–14 In
three studies, contrast enhancement was not used and in
another it was used but the RAMRIS was mainly evaluated
on synovial membrane volumes obtained from the STIR
images.7–9,11
Synovitis can be measured by MRI without the use of
paramagnetic contrast agents or comparing pre- and post-
contrast images. In the first case, fat suppression sequences
are commonly used which evidence tissues with high
water content, such as inflamed synovial membrane and
synovial fluid, after exclusion of fat. The advantages of
this method are that it is completely non invasive and that
the costs, contraindications and the possible, although
uncommon, side effects of contrast agents are avoided.
The disadvantage is that it is anatomically imprecise
because it cannot fully discriminate between synovitis
and synovial fluid effusion. As a consequence, i.v. gadoli-
nium is necessary to precisely quantify the volume of
inflamed synovial membrane. The most diffused method
to assess post-contrast enhancement of the synovial mem-
brane is the RAMRIS, a semiquantitative evaluation of
three slices of the wrist and of the metacarpophalangeal
joints on a subjective scale between 0 (no enhancement)
and one to three (mild, moderate, and severe) by thirds of
the presumed maximum volume of enhanced tissue in the
synovial compartment. More recently, dynamic, contrast-
enhanced MRI (DCE-MRI) has been proposed as an
objective method to study synovitis by extracting curves
from the sequential acquisition of repeated fast T1-
weighted sequence during intravenous infusion of gadoli-
nium. The focus can be put on a small region of interest
(ROI) manually placed in the area with most visual
enhancement or on all images in a fully automated
approach. The second method should be better for it is
more rapid and reproducible, and avoids motion artifacts.
It also shows a good correlation with the traditional
RAMRIS.15
The aims of this study were to evaluate a group of TCZ-
treated RA patients using extremity-dedicated, contrast-
enhanced MRI, and assess the usefulness of DCE-MRI
using a new computerised technique devised to quantify
inflammatory synovial neoangiogenesis and vasodilatation.16
Patients And Methods
Patients
The study involved adult outpatients with moderate or
severe, active RA (disease activity score 28 C-reactive
protein (DAS-28 CRP) >3.2, swollen joint count ≥6, ten-
der joint count ≥8) diagnosed on the basis of the 1987
American Rheumatism Association (ACR) criteria.17
The other inclusion criteria were a disease duration of
at least six months, a poor response to at least three
months’ previous treatment with a stable dose of non-
biological DMARDs, no previous use of biological treat-
ment, and the inflammatory involvement of at least one
wrist at baseline. Patients who had received intra-articular
or parenteral corticosteroids in the previous six weeks
were excluded, as were those who had received previous
treatment with a biological agent.
The patients gave their written informed consent to the
study, the protocol of which (EudraCTNo. 2009 012185–32)
was approved by the Independent Ethics Committees of the
11 participating centres before any study-related procedure
was started.
Treatments
TCZ 8 mg/kg was intravenously administered by means of
a 60 min infusion every four weeks for a total of 12
infusions. Oral corticosteroids, non-steroidal anti-inflam-
matory drugs, methotrexate (MTX) or other non-biological
DMARDs were continued at a stable dose, unless tapering
was required for safety reasons. Up to the maximum
recommended doses of additional analgesics could be
used to control pain except in the 24 hrs preceding a
visit that included the recording of efficacy measures.
Methods
All of the centres performed MRI using a 0.2T, extremity-
dedicatedArtoscan unit (Esaote, Genoa, Italy) equippedwith a
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permanent magnet and a dedicated, 13 cm diameter hand and
wrist coil.18 MRI examinations were performed at baseline
and at weeks 2, 4, 12, 24, and 48. The imaging technique was
standardised during the course of a number of practical meet-
ings. Cushions were used to hold the most severely affected
hand (or the dominant hand in the case of symmetrical invol-
vement) in a neutral position with the fingers extended and
thumb up. The 120 mm field of view allowed an evaluation of
the carpal bones, proximal metacarpal (MCP) heads, distal
radius and ulna. After the first scan, the hand was repositioned
to evaluate the MCP and proximal interphalangeal (PIP)
joints. Since contrast infusion was performed after the first
positioning of the hand, the RAMRIS for synovitis was calcu-
lated only for the wrist and not for the metacarpophalangeal
joints. The sequences used were: a) pre- and post-enhance-
ment Turbo 3D T1-weighted sequences [TR(repetition time)/
TE(echo time)=35/16 ms; matrix=192x160; FOV (field-of-
view) =140x140; slice thickness 0.8 mm; interslice gap
0 mm] recorded in the coronal plane with subsequent recon-
struction of the remaining planes; b) coronal and axial STIR
sequences (TR/TE=1500/24 ms [coronal] and 2400/24
[axial]; matrix=192x160 [coronal] and 192x144 [axial];
FOV=160x160; slice thickness 3 mm [coronal] and 4 mm
[axial]; interslice gap 0.3 mm [coronal] and 0.4 mm [axial]);
c) axial Turbo Spin Echo T2-weighted sequences (TR/
TE=3520/80 ms; matrix=256x192, FOV=150x150; slice
thickness 4 mm; interslice gap 0.4 mm); and d) dynamic,
contrast-enhanced (DCE) MRI using Spin Echo sequences
(TR/TE=100/16 ms; matrix=160x128; FOV=170x170; slice
thickness 5 mm; interslice gap 0 mm; 3 slices). After a bolus
injection of 0.2 mL/kg of Gadolinium-DTPA (diethylenetria-
mine penta-acetic acid) (Magnevist; Schering, Berlin,
Germany), 20 consecutive fast spin-echo images of the wrist
were acquired every 18 seconds. The shape of the resulting
curve reflects the time-dependent tissue uptake of the contrast:
tissues with inflammatory neovascularisation and vasodila-
tion, such as the active synovial membrane, rapidly assume
contrast (wash-in phase), and then reach a plateau followed by
a washout phase. DCE MRI was used to investigate a ROI in
the area of the synovial membrane with the greatest visual
enhancement. The rate of early enhancement (REE) per sec-
ond during the first 55” was calculated using the formula:
REE55 = (S55-S0)/(S0x55)*100%, and relative enhancement
(RE) at t seconds was calculated using the formula: REt = (St-
S0)/S0*100%, where S0 and St are the signal to noise ratios
between the signal measured in the ROI and the standard
deviation (SD) of the background noise before and t seconds
after the injection of the contrast medium. The signal was
normalised to an external reference in order to reduce noise.
REE is the slope of the curve of contrast uptake tangential to
the angle (the steeper the curve, the greater the inflammation),
RE indicates the steady state of enhancement.
The images were also evaluated using a novel computer-
aided technique for the automated processing of the DCE
MRI of the whole synovial membrane (Dynamika®,
ImageAnalysis, UK) after motion correction and filtering.16
The area to be investigated was chosen semi-automatically,
within a manually outlined ROI drawn quickly around the
joint excluding large artefacts such as blood vessels. The
signal intensity (SI) vs time curves are extracted from each
voxel and automatically assigned to one of four patterns of
contrast uptake (“no enhancement”, “persistent enhance-
ment”, “plateau” or “washout”), which are in effect linear
models approximating the SI curves. The “no enhancement”
and “persistent enhancement” patterns are typical of tissues
unaffected by disease and background, whereas the “pla-
teau” and “washout” patterns are typical of perfused tissues
such as inflamed joints or blood vessels. The resulting
parameters include maximum enhancement (ME), the %
variation in enhancement from baseline, which is higher
in more perfused tissues; the initial rate of enhancement
(IRE), the slope of the enhancement curve expressed in %
per second, with the highest values corresponding to the
most vascularised tissues; Ntotal or the total number of
enhancing pixels; Nplateau or the number of pixels for
which the corresponding curves reach the intensity plateau;
Nwashout or the number of pixels reaching the washout
phase; and Ntotal*IRE and Ntotal*ME, which are composite
parameters that reflect the volume and degree of
inflammation.
Antero-posterior radiographs of the hands and wrists
were obtained at baseline and after 48 weeks, and evalu-
ated centrally at the Genoa centre using the total modified
Sharp score (TMSS). All the MRI images were read in the
same centre; in particular the STIR images underwent
standardisation of the look-up-table to improve contrast.
The primary efficacy endpoints of the study were: i)
the extent and degree of wrist synovitis at week 4 as
measured using the Rheumatoid Arthritis MRI Score
(RAMRIS); and ii) the degree of synovitis at week 4
quantified on the basis of the REE and RE of dynamic,
gadolinium-enhanced MRI of the wrist. The secondary
efficacy endpoints were the MRI findings at all time
points, radiographic changes in the hands, and the clinical
and laboratory evaluations usually performed in RA
patients.
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Clinical Efficacy
Disease activity was assessed at each study visit using the
DAS 28, a composite of 28 tender joint counts, 28 swollen
joint counts, CRP levels, and the patients’ visual analogue
scale assessment of disease activity. The HAQ disability
index was also calculated. The percentage of patients with
a DAS 28-based response according to EULAR (20) was
recorded.
Statistics
A sample size of 70 patients had 90% power to detect a
mean difference of 0.9 in RAMRIS for synovitis between
baseline and week 4, assuming a SD of 2 and using a paired
t-test with a 0.017 two-sided significance level, considering
the multiplicity of statistical test performed. Efficacy and
safety were analysed in the intent-to-treat (ITT) population
(i.e. all of the subjects who received at least one dose of
treatment). The primary efficacy endpoints were also eval-
uated in the per-protocol (PP) population (i.e. all of the
patients in the ITT population without major protocol viola-
tions). A paired t-test was used to evaluate the changes in
the primary endpoints from baseline to week 4, with
Bonferroni correction because of the multiplicity of tests.
The Bonferroni correction was considered adequate despite
of dependence of outcomes as the more conservative
approach, taking into account the explorative nature of the
analysis. The changes in the efficacy measures from base-
line to any post-baseline time point were evaluated using a
repeated ANOVA model. The original data were rank trans-
formed when not normally distributed. The last observation
carried forward (LOCF) method was used in the case of
missing post-baseline data.
Results
Fifty-eight RA patients (87.9% Caucasian; 77.6% female;
mean age 51.5±13.0 years; mean disease duration 9.2±9.1
years) were recruited at the 11 study centres. The most
frequent RA treatments were methotrexate (44 patients,
75.9%) and prednisone (27 patients, 46.6%). Eight patients
(13.8%) discontinued the study prematurely, and 43
(74.1%) were included in the PP population.
Treatment with TCZ was associated with a rapid and
progressive improvement in disease activity. There was a
significant decrease from baseline in mean DAS-28 CRP
levels and the HAQ disability index after just two weeks
of treatment, and this was maintained until the end of the
study. The mean changes in DAS-28 CRP and HAQ from
baseline to the end of the study were respectively −3.07 ±
1.27 and −0.67±0.09. A good response based on DAS-28
ACR criteria (i.e. a score of <3.2 with an improvement
from baseline of >1.2) was observed in 71.6% of the
patients at week 24, and in 77.3% at week 48 (Figure 1).
Table 1 shows the results of the primary efficacy end-
points in the ITT population. By week 4, there was a
significant decrease from baseline in the mean RAMRIS
for wrist synovitis (p=0.018), whereas mean REE and RE
did not significantly change. The results in the PP popula-
tion were consistent with those of the ITT analysis.
In the ANOVA model, the decrease from baseline in
mean wrist RAMRIS was significant as early as two weeks
after the start of treatment, and this was maintained until
the end of the study. The improvement in REE was slower
and did not start until week 12, and the decrease in RE was
significant only after 24 weeks. The decrease in the
RAMRIS for synovitis was similar in all of the individual
wrist joints (data not shown). The improvement in MRI
measures constantly increased at every time point.
Among the MRI parameters measured using Dynamika®
software (Table 2), Nwash-out and Ntotal*IRE significantly
decreased from baseline by week 12, whereas ME,
Ntotal*IRE and Ntotal*ME decreased by week 24. By week
48, there was a statistically significant decrease in mean IRE,
ME, Ntotal, Nplateau, Nwash-out, Ntotal*IRE and Ntotal*ME.
Figure 2 shows the changes in ME in an individual patient.
Figure 3 shows the RAMRIS for bone marrow edema
(BME) and erosion. The mean aggregate BME score (wrist
+MCP sites) significantly decreased from baseline to week
24 (mean change −6.70 ± 10.98; p=0.002) and week 48
(mean change −8.30±13.06; p=0.001). Similarly, the mean
number of bones with BME progressively decreased from
7.91±6.27 at baseline to 4.88±5.29 at week 48 (p<0.0001).
Figure 4 shows the evolution of BME during TCZ treatment
Figure 1 Percentage of patients showing changes in EULAR response during TCZ
treatment.
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in a representative patient. There was no change from base-
line to week 48 in the mean aggregate erosion score (mean
change 0.36±4.17), or the scores for the wrist (mean change
0.34±3.67) or MCP joints (mean change 0.98±1.18), and the
number of bones with erosions at baseline (8.07±4.71) did
not change at end of study (mean change −0.04±2.81).
Similarly, there were no radiographic changes in the hands
from baseline to week 48 as evaluated by the TMSS (mean
Table 1 Wrist Synovitis In The ITT Population
Baseline Week 2 Week 4 Week 12 Week 24 Week 48
RAMRIS No. of pts 55 45 49 50 49 47
Mean (SD) 5.78 (2.72) -0.44 (1.03)* -0.88 (1.56)° -1.28 (1.96)# -1.94 (2.34)# -1.60 (2.42)#
Median 6.00 0.00 -1.00 -1.00 -2.00 -2.00
RE No. of pts 54 44 45 49 48 45
Mean (SD) 99.25 (57.85) 5.80 (46.14) -0.48 (47.85) -9.27 (50.07) -26.48 (57.99)° -19.74 (74.08)
Median 103.45 3.00 -6.50 -8.00 -24.10 -20.40
REE No. of pts 54 44 45 49 48 45
Mean (SD) 1.19 (1.04) -0.04 (1.11) -0.10 (0.86) -0.48 (0.96)* -0.57 (0.87)° -0.66 (1.24)°
Median 1.00 0.00 0.00 -0.20 -0.45 -0.30
Notes: *P<0.005, °p<0.01, #p<0.001 vs baseline in the ANOVA model.
Abbreviations: RAMRIS, Rheumatoid Arthritis MRI Score; RE, relative enhancement; REE, rate of early enhancement.
Table 2 MRI Parameters As Measured Using Dynamika® Software (ITT population)
Baseline Week 2 Week 4 Week 12 Week 24 Week 48
IRE No. of pts 49 39 43 43 39 32
Mean (SD) 0.005 (0.004) -0.000 (0.003) -0.000 (0.004) -0.001 (0.004) -0.001 (0.006) -0.002 (0.004)°
Median 0.005 -0.000 -0.001 -0.002 -0.001 -0.002
ME No. of pts 49 39 43 43 39 32
Mean (SD) 1.606 (0.422) 0.176 (1.264) -0.039 (0.289) -0.076 (0.393) 0.024 (1.143)° -0.177 (0.416)°
Median 1.599 0.027 0.005 -0.046 -0.081 -0.112
Ntotal No. of pts 48 38 42 42 38 31
Mean (SD) 3155.7 (1677.2) 159.7 (1407.7) -544.4 (1251.4) -605.4 (1541.2) -560.6 (1703.3) -974.2 (1606.1)°
Median 3309.0 -51.00 -437.0 -830.0 -719.5 -1108.0
Npersistent No. of pts 49 39 43 43 39 32
Mean (SD) 182.04(157.15) -22.97 (124.88) -26.65 (248.49) 15.93 (255.49) -12.46 (153.01) -0.53 (219.74)
Median 132.0 0.00 -18.00 -4.00 -21.00 5.00
Nplateau No. of pts 49 39 43 43 39 32
Mean (SD) 1839.6 (994.1) 135.4 (936.6) -183.8 (855.9) -253.7 (1054.6) -353.4 (1136.0) -635.7 (1019.1)*
Median 1769.0 140.0 -161.0 -205.0 -509.0 -676.0
Nwashout No. of pts 49 39 43 43 39 32
Mean (SD) 1167.2 (783.2) 10.0 (721.7) -349.3 (708.8) -396.4 (664.9)° -280.2 (852.6) -358.3 (798.9)*
Median 1036.0 61.0 -178.0 -212.0 -110.0 -307.5
Ntotal*IRE No. of pts 48 38 42 42 38 31
Mean (SD) 6.01 (5.93) -0.05 (5.32) -1.15 (5.37) -2.56 (5.35)* -2.51 (5.41)* -4.84 (6.13)#
Median 4.15 -0.03 -1.08 -1.77 -1.38 -3.49
Ntotal*ME No. of pts 48 38 42 42 38 31
Mean (SD) 1882.4 (1267.5) 1009.9 (6532.7) -431.3 (1066.9) -535.8 (1282.6) -597.1 (1320.7)* -793.6 (1168.6)#
Median 1679.0 -43.9 -209.6 -437.0 -411.5 -761.5
Notes: *P<0.005, °p<0.01, #p<0.001 vs baseline (repeated measure ANOVA).
Abbreviations: IRE, initial rate of enhancement; ME, maximal enhancement; Ntotal, total number of enhancing voxels; Nwashout, number of voxels with washout.
Dovepress Cimmino et al
Biologics: Targets and Therapy 2020:14 submit your manuscript | www.dovepress.com
DovePress
17
 
Bi
ol
og
ics
: T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
77
.8
3.
12
.1
89
 o
n 
02
-M
ar
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
change 1.46±5.66), or its component erosion score (mean
change 0.31±1.07) or joints synovial narrow (JSN) score
(mean change 1.15±5.42).
Fifty patients (86.2%) experienced at least one treat-
ment emergent adverse event (TEAE, AEs started at or
after the first administration of the study treatment),
mainly infections (39.7%) and laboratory abnormalities
(36.2%). However, only two patients (3.4%) discontinued
the study prematurely because of AEs (erythematous rash,
face edema and tachycardia in one patient, and herpes
zoster in the second), although 27 (46.6%) required TCZ
dose modifications.
Discussion
This is the largest study in which the effect of TCZ was
analyzed using contrast-enhanced MRI, showing that the
drug is efficacious as early as two weeks after the start of
treatment, although the number of patients was lower than
that calculated for the defining the power of the study
because of enrolment difficulties in some of the participat-
ing centres. There are only a few MRI studies evaluating
TCZ treatment in RA patients. One low-field, extremity-
dedicated MRI study of a small number of patients refrac-
tory to anti-tumour necrosis factor (TNF) biological agents
showed improvements in MRI indices after 44 weeks, but
no clear short-term (20-week) response.8 Another study
administered TCZ to 29 RA patients and evaluated its
effects after two and five months using a 1.5T machine:
TCZ improved the patients’ clinical and laboratory para-
meters, but there was no change in the MRI findings.7 The
delayed or absent MRI effects may have been due to
difficulties in clearly distinguishing bone erosion and
BME, the relatively large fields of view with a low spatial
resolution (a heart coil was used in one study), the use of
scores other than RAMRIS and, most importantly, the fact
that MRI without contrast enhancement was used, which is
less sensitive to treatment-induced changes in synovitis.
Furthermore, the studies used STIR sequences to evaluate
synovitis although they have been shown to be less sensi-
tive than post-contrast sequences in this setting.19–20
Conaghan et al compared the efficacy of TCZ mono-
therapy and combined TCZ and DMARD treatment using
extremity-dedicated MRI and the same machine as that
used in our study. TCZ alone improved synovitis and
osteitis as early as two weeks after the start of the study,
Figure 2 Changes in ME as evaluated by the Dynamika software in a representative patient. Note the progressive improvement in synovitis until week 24 and its worsening
at week 48, which corresponded to a slight and temporary clinical deterioration.
Figure 3 Bone marrow edema (blue) and erosion aggregate scores (light grey) at
the different time points (ITT population). Mean values ± SD. *p<0.01 vs baseline
(repeated measure ANOVA).
Figure 4 Changes in bone marrow edema (BME) as evaluated by means of STIR sequences in an individual patient. Note the progressive improvement in BME, which was
paralleled by a decrease in the corresponding RAMRIS value from 42 at baseline to 18 after 48 weeks. The STIR images also showed an improvement in synovitis during the
same period.
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whereas the combined treatment showed no significant
efficacy after 52 months.9
On the contrary, we found that TCZ rapidly decreased
synovitis as evaluated by means of contrast-enhanced MRI
in a cohort of patients concomitantly treated with
DMARDs. There is no apparent reason why TCZ should
be more effective on MRI findings when given alone
rather than in combination with DMARDs, but the differ-
ences between our findings and those of Conaghan et al
may be due to our larger patient population, which prob-
ably allowed statistical significance to be reached.9
We observed a statistically significant decrease in the
RAMRIS for wrist synovitis after only two weeks of TCZ
treatment, which was maintained until the end of the study,
thus paralleling the rapid and continuous clinical efficacy
of TCZ. The drug is therefore not acting on the composite
indices of disease activity by only modifying inflammation
markers, but also has a profound effect on synovitis. The
quantitative assessment of the degree of synovitis by
means of dynamic, gadolinium-enhanced MRI of the
wrist showed statistically significant improvements in
REE from baseline to weeks 12, 24 and 48, and in RE to
week 24. There were also statistically significant improve-
ments from baseline to week 48 in the MRI parameters
measured using Dynamika® software, a system that incor-
porates efficient data processing and analysis techniques in
order to ensure significantly better data quality.15,16
Contrary to our expectations, the semi-quantitative
RAMRIS for synovitis was apparently more sensitive to
change than the theoretically more objective (because con-
tinuous and less observer-dependent) DCE-MRI, some-
thing that cannot be explained on the basis of the
interpretation of the RAMRIS readers because they were
blinded to the timing of the images, an approach which
was deemed more appropriate because of the absence of a
control group.
It has been shown that the multi-planar nature of MRI
makes it more sensitive than conventional radiography in
detecting the progression of bone erosion, and it has also
been found that there is a high level of agreement between
low-field extremity and high-field conventional MRI in
detecting bone erosions and synovitis.21,23
Previous MRI studies of the progression of bone ero-
sions in RA have shown that, despite its clinical efficacy,
one year of treatment with MTX was followed by an
increase in the number of patients with erosions and in
the number of erosions themselves.24 We did not find any
radiographic or MRI evidence of the progression of bone
erosions during the 48 weeks of TCZ therapy, a finding
that is in line with that of Conaghan et al.9
MRI-detected BME is considered an interim phase
between synovitis and bone erosion, and seems to be a
strong predictor of subsequent radiographic progression in
patients with early RA.24 Although low-field MRI is only
moderately sensitive in detecting BME,22 we found that
TCZ treatment was associated with a decrease in wrist and
MCP BME that became significant after 24 weeks. This
result is in keeping with the study of Bensaoud et al, who
also noted a significant decrease of the RAMRIS BME
score after 6 months of TCZ treatment but constrasts with
that of Hirota et al, who noted it only after 52 weeks.10,11
However, in Bensaoud et al study, only two MRIs were
performed at baseline and at 6 months, whereas in our
study MRI follow-up was done regularly on six occasions.
As a result we can state that the minimum time necessary
for BME to improve during TCZ treatment is between 12
and 24 weeks. Our finding that one year’s treatment with
TCZ significantly reduced synovitis and edema in patients
with moderate to severe active RA, and the fact that there
was no evidence of any further progression of bone ero-
sions, support the finding of recent clinical trials that TCZ
is a disease-modifying agent that limits joint damage
regardless of its effects on disease activity.25
In line with previous findings, we found that the com-
bination of TCZ and DMARDs was rapidly effective in
inducing rapid and sustained improvements in the signs
and symptoms of RA.4
The marked decrease from baseline in mean DAS-28 CRP
(and its components) that was evident after just two weeks of
treatment was maintained for the 48 weeks of the study.
The limitations of this study are the relatively small
number of patients and the lack of a control group. Its
strengths are the large number of images recorded over
one year, the use of an intravenous contrast medium in
order to visualise synovitis, the use of DCE-MRI, and the
fact that the same type of machine was used in the differ-
ent study centres. This fact, which is uncommon in multi-
centre MRI trials, allowed the meticulous standardisation
of the procedures and of the interpretation of the results.
In conclusion, the results of this study of a population of
Italian patients with moderate to severe active RA not
responding to DMARD therapy show that combined treat-
ment with TCZ 8 mg/kg and DMARDs is highly effective in
controlling MRI wrist synovitis and bone marrow edema,
clinical parameters, and erosive progression. Further double-
blind and placebo-controlled trials are needed to investigate
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the effect of TCZ on the different parameters of contrast-
enhanced MRI synovitis in more detail.
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